CD19 CAR T-cell therapy has a dramatic effect on R/R B-ALL patients achieving high CR rates, but approximately 20-50% of patients relapse at 6 months [8–11, 27]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.